暴露前预防(PrEP)相关的HIV监测与自检
本文综述了HIV暴露前预防(PrEP)的现状与进展,指出口服PrEP的挑战在于服药依从性,长效注射制剂可能改善依从性。HIV检测在PrEP项目中至关重要,方法包括实验室抗原/抗体免疫分析、快速检测加反射确认和RNA检测。世界卫生组织鼓励使用快速HIV自检以克服提供者检测的障碍,目前自检主要为抗体快速检测,未来需要更多药物选择和高灵敏度自检方法。
要点
- 口服PrEP的主要挑战是服药依从性,长效注射制剂可能改善。
- HIV检测方法包括实验室抗原/抗体免疫分析、快速检测加反射确认和RNA检测。
- 世界卫生组织鼓励快速HIV自检,但当前自检主要为抗体快速检测。
核心结论
- HIV PrEP及相关监测是HIV预防的重要组成部分。
- 更有效的药物将提高PrEP效果,更可及的服务和高灵敏度检测(尤其是自检)可改善HIV预防。
研究设计与样本
- 本文为综述,回顾PrEP当前实践和近期发展。
主要发现
- 每日口服HIV PrEP是常见方法,挑战在于服药依从性。
- 近期长效注射药物可用于HIV PrEP,可能改善依从性。
- HIV检测方法包括实验室抗原/抗体免疫分析、快速检测加反射确认和RNA检测。
- 世界卫生组织鼓励使用快速HIV检测进行自检,因为提供者检测可能阻碍PrEP uptake。
- 当前HIV自检方法主要为抗体快速检测。
关键数值与推荐
- 目前可用的HIV PrEP药物是核苷类逆转录酶抑制剂和整合酶抑制剂。
- 在PrEP前、长时间暂停后重启PrEP时以及PrEP维持期间需要进行HIV检测。
临床怎么用
- 在PrEP前、重启和维持期间应进行HIV检测以确认未感染。
- 可考虑使用快速HIV自检以提高PrEP可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) encompasses the use of antiviral medications to prevent HIV acquisition in individuals without HIV who are at risk. Currently available HIV PrEP medications are nucleoside reverse transcriptase inhibitors and integrase inhibitors. HIV testing is required to confirm that patients do not have an HIV infection before PrEP, when restarting PrEP after a long pause, and during ongoing maintenance of PrEP. CONTENT: This article reviews current practices and recent developments in PrEP. Daily oral HIV PrEP is a common approach for HIV PrEP. The challenge with oral HIV PrEP is medication adherence. Recently, long-acting injectable medications for HIV PrEP have become available, which may improve adherence. HIV testing plays a critical role in PrEP programs. Methods for HIV testing for PrEP programs include laboratory-based antigen/antibody immunoassays, rapid testing with reflex confirmation, and RNA testing. The World Health Organization encourages the use of rapid HIV assays for self-testing because provider-administered testing may be a barrier to PrEP uptake. Currently available HIV self-testing (HIVST) methods are primarily antibody-based rapid assays. To improve the effectiveness of HIV PrEP, a greater range of medications, including novel long-acting antiretroviral agents, broadly neutralizing antibodies, and other drugs, are needed. Additionally, more accessible PrEP service delivery and high-sensitivity HIV tests, especially nucleic acid-based HIVST methods, are warranted. SUMMARY: HIV PrEP and related monitoring are essential parts of HIV prevention. More effective medications will improve the effectiveness of HIV PrEP, and more accessible PrEP service delivery and high-sensitivity HIV tests, especially HIVST methods, can improve HIV prevention with PrEP.
引用
- Zhu Y, Sell J. Pre-Exposure Prophylaxis (PrEP)-Associated HIV Monitoring and Self-Testing. Clin Chem. 2026. PMID: 41335516. doi:10.1093/clinchem/hvaf155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。